Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

ABSTRACT: This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.

DISEASE(S): Colon Cancer,Colorectal Neoplasms

PROVIDER: 2018987 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR